Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients

European Journal of Clinical Pharmacology

Volumn 53, Issue 1, 1997, Pages 51-56

  Hildebrand, M ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Iloprost; Oral treatment; Thromboangiitis obliterans (TAO); Tolerability

Indexed keywords

ILOPROST;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BUERGER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FLUSHING; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SUSTAINED RELEASE PREPARATION;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; HUMANS; ILOPROST; INFUSIONS, INTRAVENOUS; MALE; PLATELET AGGREGATION INHIBITORS; THROMBOANGIITIS OBLITERANS;

EID: 0030884397     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050336     Document Type: Article

References (20)

1. Moncada S, Gryglewski RJ, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663-665
2. Moncada S, Gryglewski RJ, Bunting S, Vane JR (1976) A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance prostaglandin X which prevents platelet aggregation. Prostaglandins 12: 715-737
3. 1, with thier effect on platelet aggregation. Prostaglandins Leukot Med 10: 197-212
4. 2 in-vitro. Naunyn-Schmiedeberg's Arch Pharmacol 316: 252-265
5. Skuballa W, Vorbrüggen H (1983) Synthesis of iloprost (ZK 36374): a chemically stable and biologically potent prostacyclin analog. Adv Prostaglandin Thromboxane Leukot Res 11: 299-305
6. Schillinger E, Krais T, Stock G (1987) Iloprost. In: Scriabine A (ed) New drugs annual: cardiovascular drugs. Raven Press, New York, pp 209-231
7. Krause W, Krais T (1986) Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 30: 61-68
8. Krause W, Krais T (1987) Pharmacokinetics and pharmacodynamics of radiolabelled iloprost in elderly volunteers. Eur J Clin Pharmacol 32: 597-607
9. Diehm C (1987) Placebo-kontrollierte doppelblinde 13-Center-Studie zum Nachweis der therapeutischen Wirksamkeit von Iloprost bei Patienten mit arterieller Verschlußkrankheit (Stad IV). Klin Wochenschr 65: 38-39
10. Fissinger JN, Schäfer M (1990) Trial of iloprost vs. aspirin treatment for critical limb ischemia of thromboangiitis obliterans. Lancet 35: 555-557
11. Torley HI, Madhok R, Capell HA, Brouwer RML, Maddison PJ, Black CM, Englert H, Dormandy JA, Watson HR (1991) A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 50: 800-805
12. Kyle MV, Belcher G, Hazleman BL (1992) Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon. J Rheumatol 19: 1403-1407
13. Hildebrand M, Krause W, Oberender HA, Zurdel-Dillinger S, Jünger M, Bodenburg H (1990) Pharmacokinetics of Iloprost in PAOD patients. Eicosanoids 3: 145-148
14. Hildebrand M, Mc Donald FM, Windt-Hanke F (1991) Characterization of oral sustained release preparations of iloprost in a pig model by plasma level monitoring. Prostaglandins 41: 473-486
15. Hildebrand M, Pfeffer M, Mahler M, Staks T, Windt-Hanke F, Schütt A (1991) Oral iloprost in healthy volunteers. Eicosanoids 4: 149-154
16. Hildebrand M (1994) Interspecies comparison of pharmacokinetic parameters of an oral sustained release preparation of iloprost. Drug Dev Ind Pharma 20: 1367-1376
17. Hildebrand M, Kraus C, Windt-Hanke F, Iffert B, Scheuermann H (1995) In vitro in vivo correlation of drug liberation with an extended release oral dosage form for iloprost in man. Drug Dev Ind Pharma 21: 2339-2353
18. Hildebrand M, Nieuweboer B, Biere H, Klar U, Seemann G, Krause W, Jakobs U (1990) Development, validation and practical use of a sensitive and specific RIA for the determination of iloprost. Eicosanoids 3: 165-169
19. 2-mimetic, by conventional RIA and SPA. Eicosanoids 5: 5-8
20. Heinzel G, Woloszczak R, Thomann R (1993) TOPFIT 2.0: pharmacokinetic and pharmacodynamic data analysis system for the PC. Fischer, Stuttgart